Balance Sheet: Assets
Quarterly Data
The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.
Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Reportable Segments
- Enterprise Value to FCFF (EV/FCFF)
- Selected Financial Data since 2005
- Net Profit Margin since 2005
- Debt to Equity since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Abbott Laboratories, consolidated balance sheet: assets (quarterly data)
US$ in millions
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
The financial data reveals various trends and fluctuations in Abbott Laboratories' quarterly items over the period from March 2020 to March 2025.
- Cash and Cash Equivalents
- Cash and cash equivalents increased significantly from $3,377 million in March 2020 to a peak near $9,799 million in December 2021, followed by a general decline to $6,532 million in March 2025. This suggests an initial accumulation of liquid assets that taper off towards the end of the analyzed period.
- Short-term Investments
- Short-term investments remained relatively stable, fluctuating between approximately $230 million and $480 million without a clear upward or downward trend.
- Trade Receivables, less Allowances
- Trade receivables showed an overall increasing trend, starting at $5,292 million in March 2020 and rising to $7,327 million by March 2025, indicating growing sales or credit extended to customers.
- Inventories
- Inventories experienced growth from $4,568 million in March 2020 to a peak of $6,813 million in September 2024, before slightly decreasing to $6,639 million in March 2025. This points to an accumulation of stock possibly to meet anticipated demand.
- Materials
- The materials component of inventory steadily grew from $1,080 million in March 2020 to a high around $2,022 million in June 2023, then showed some fluctuations decreasing to $1,686 million by March 2025. This may indicate shifts in procurement or cost management strategies.
- Finished Products and Work in Process
- Finished products rose from $2,873 million in March 2020 to approximately $4,063 million by September 2024, while work in process fluctuated with a moderate upward trend, peaking around $890 million in September 2024. Both suggest increased production activities over time.
- Prepaid Expenses and Other Receivables
- This category stayed fairly stable, oscillating between roughly $1,842 million and $2,570 million without a definitive trend, reflecting consistent operational costs and minor variations in advance payments or receivables.
- Current Assets
- Current assets increased from $15,498 million in March 2020 to a peak around $25,224 million in December 2022, then declined somewhat to $23,153 million by March 2025. This growth followed by slight reduction corresponds to the patterns seen in cash, receivables, and inventories.
- Property and Equipment, Net
- Net property and equipment grew moderately from $7,907 million in March 2020 to $10,932 million in March 2025, reflecting continued investment in fixed assets despite some adjustments from depreciation.
- Intangible Assets, Net of Amortization
- Intangible assets showed a pronounced declining trend, dropping from $16,265 million in March 2020 to $6,261 million by March 2025. This steady decrease indicates consistent amortization or impairment of intangible assets.
- Goodwill
- Goodwill values remained relatively stable with minor fluctuations around $23,000 million, suggesting limited acquisition activity or stable valuations for goodwill.
- Deferred Income Taxes and Other Assets
- This category showed strong growth late in the period, especially from December 2024 ($8,011 million) to March 2025 ($16,836 million), which may reflect significant changes in tax assets or other long-term asset classifications.
- Long-term Assets
- Long-term assets remained broadly stable with minor fluctuations, ending higher at $58,295 million in March 2025 compared to $51,279 million in March 2020, indicating steady investment in non-current asset bases.
- Total Assets
- Total assets increased from $66,777 million in March 2020 to $81,448 million in March 2025, signaling overall asset growth despite some volatility in specific components.
In conclusion, the data indicates a period of asset growth fueled by increases in cash reserves, receivables, inventories, and fixed assets over the first half of the timeframe, followed by some stabilization and minor declines towards the latter periods. Intangible assets amortized steadily, while deferred income taxes and certain long-term assets increased notably near the end of the timeframe.